STAT+: China tightens the reins on clinical trials, even as the U.S. looks for ways to replicate its rival’s speed

China has tightened its regulations on clinical trials, even as the United States seeks to emulate China's rapid pace in research and development. For years, U.S. scientists and biotech firms have watched as China has surged ahead in research funding, patent filings, and clinical trials. Many observers have viewed this as an indicator that the U.S. must urgently reform its cumbersome clinical trial and regulatory processes.

However, a critical component of China's biomedical success - investigator-initiated trials (ITTs) - is now being tightened, and a system that helped fuel the country's remarkable achievements has come under scrutiny. ITTs allowed researchers to launch clinical studies without approval from China's National Medical Products Administration or the usual extensive review process.

This approach enabled China to accelerate the application of medical research, involve physicians in the nation's pharmaceutical innovation, and generate substantial revenue from newly approved drugs. However, these trials also raised concerns about patient safety, transparency, and the protection of intellectual property. More details are available in the full STAT+ report.